Advertisement

Ocular Cicatricial Pemphigoid

  • Swetha Dhanireddy
  • Armin Maghsoudlou
  • Janine M. Preble
  • Malinga D. Ratwatte
  • C. Stephen FosterEmail author
Chapter

Abstract

Ocular cicatricial pemphigoid is a result of immune dysfunction leading to deposition of immunoglobulins and complement at the conjunctival basement membrane zone. This can lead to irreversible scarring. Patients are treated with suitable systemic immunomodulatory treatments which are usually individualized to the patient depending on the patient’s age, disease stage, and presence of non-ocular symptoms. The approach to choosing the proper chemotherapy is through a stepladder algorithm. The ultimate goal of therapy is to treat the patient with corticosteroid-sparing systemic agent. The focus of this chapter will be the medical treatment strategies available for OCP based upon clinical severity, extent and progression of the disease.

Keywords

Ocular cicatricial pemphigoid Dapsone Azathioprine Mycophenolate mofetil Cyclophosphamide Methotrexate Plasmapheresis Rituximab Intravenous Immunoglobulin 

References

  1. 1.
    Neff AG, Turner M, Mutasim DF. Treatment strategies in mucous membrane pemphigoid. Ther Clin Risk Manag. 2008;4(3):617–26.PubMedCentralPubMedGoogle Scholar
  2. 2.
    Higgins GT, Allan RB, Hall R, et al. Development of ocular disease in patients with mucous membrane pemphigoid involving the oral mucosa. Br J Ophthalmol. 2006;90:964–7.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Kirzhner M, Jakobiec FA. Ocular cicatricial pemphigoid: a review of clinical features, immunopathology, differential diagnosis and current management. Semin Ophthalmol. 2011;26(4–5):270–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Ahmed M, Zein G, Khawaja F, Foster CS. Ocular cicatricial pemphigoid: pathogenesis, diagnosis and treatment. Prog Retin Eye Res. 2004;23(6):579–92.PubMedCrossRefGoogle Scholar
  5. 5.
    Foster CS. Cicatricial pemphigoid. Trans Am Ophthalmol Soc. 1986;84:527–663.PubMedCentralPubMedGoogle Scholar
  6. 6.
    Foster CS, Wilson LA, Ekins MB. Immunosuppressive therapy for progressive ocular cicatricial pemphigoid. Ophthalmology. 1982;89:340–53.PubMedCrossRefGoogle Scholar
  7. 7.
    Chan RY, Bhol K, Tesavibul N, et al. The role of antibody to human beta 4 integrin in conjunctival basement membrane separation: possible in vitro model for ocular cicatricial pemphigoid. Invest Ophthamol Vis Sci. 1999;40:2283–90.Google Scholar
  8. 8.
    Foster CS, Ahmed AR. Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study. Ophthalmology. 1999;106:2136–43.PubMedCrossRefGoogle Scholar
  9. 9.
    Dantzig PI. Immunosuppressive and cytotoxic drugs in dermatology. Arch Dermatol. 1974;110:393–406.PubMedCrossRefGoogle Scholar
  10. 10.
    Mondino BJ, Brown SI. Ocular cicatricial pemphigoid. Ophthalmology. 1981;88:95–100.PubMedCrossRefGoogle Scholar
  11. 11.
    Foster CS, Neumann R, Tauber J. Long-term results of systemic chemotherapy for ocular cicatricial pemphigoid. Doc Ophthalmol. 1992;82:223–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Stephens CR. The structure of aureomycin. J Am Chem Soc. 1954;76:3568–75.CrossRefGoogle Scholar
  13. 13.
    Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol. 2006;54:258–65.PubMedCrossRefGoogle Scholar
  14. 14.
    Webster GF, Leyden JJ, McGinley KJ, et al. Suppression of polymorphonuclear leukocyte chemotactic factor production in Propionibacterium acnes by sub-minimal inhibitory concentrations of tetracyclines and erythromycin. Antimicrob Agents Chemother. 1982;21:770–2.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Webster G, Del Rosso JQ. Anti-inflammatory activity of tetracyclines. Dermatol Clin. 2007;25:133–5.PubMedCrossRefGoogle Scholar
  16. 16.
    Poskitt L, Wojnarowska F. Treatment of cicatricial pemphigoid with tetracycline and nicotinamide. Clin Exp Dermatol. 1995;20:258–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Mallon E, Wojnarowska F. Cicatricial pemphigoid presenting with unusual palmar involvement, successfully treated with a combination of nicotinamide and tetracycline. Clin Exp Dermatol. 1994;19:526–30.PubMedCrossRefGoogle Scholar
  18. 18.
    Kohler IK, Lorincz AL. Erythema elevatum diutinum treated with niacinamide and tetracycline. Arch Dermatol. 1980;116:693–5.PubMedCrossRefGoogle Scholar
  19. 19.
    Berk MA, Lorincz AL. The treatment of bullous pemphigoid with tetracycline and niacinamide a preliminary report. Arch Dermatol. 1986;122:670–4.PubMedCrossRefGoogle Scholar
  20. 20.
    Thornfeldt CR, Menkes AW. Bullous pemphigoid controlled by tetracycline. J Am Acad Dermatol. 1987;16:305–10.PubMedCrossRefGoogle Scholar
  21. 21.
    Pereyo NG, Davis LS. Generalized bullous pemphigoid controlled by tetracycline therapy alone. J Am Acad Dermatol. 1995;32(1):138–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Smith CJ, Sayles H, Mikuls TR, Michaud K. Minocycline and doxycycline therapy in community patients with rheumatoid arthritis: prescribing patterns, patient-level determinants of use, and patient-reported side effects. Arthritis Res Ther. 2011;13:2–8.CrossRefGoogle Scholar
  23. 23.
    Fourneau E. Action antistreptococcique des dérivés sulfurés organiques. CE Acad Sci. 1937;204:1763.Google Scholar
  24. 24.
    Rook A, Waddington E. Pemphigus and pemphigoid. Br J Dermatol. 1953;65:425–31.CrossRefGoogle Scholar
  25. 25.
    Persons JR, Rogers RS. Bullous pemphigoid responding to sulfapyridine and the sulfones. Arch Dermatol. 1977;113:610–5.CrossRefGoogle Scholar
  26. 26.
    Wertheim MS, Males JJ, Cook SD, et al. Dapsone induced haemolytic anaemia in patients treated for ocular cicatricial pemphigoid. Br J Ophthalmol. 2006;90:516.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Fern AI, Jay JL, Young H, et al. Dapsone therapy for the acute inflammatory phase of ocular pemphigoid. Br J Ophthalmology. 1992;76:332–5.CrossRefGoogle Scholar
  28. 28.
    Doan S, Lerouic JF, Robin H, et al. Treatment of ocular cicatricial pemphigoid with sulfasalazine. Ophthalmology. 2001;108:1565–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Farber S, Diamond LK. Temporary remissions in acute leukemia in children produced by folic antagonist 4-aminopteroglutamic acid (aminopterin). N Engl J Med. 1948;238:787–93.PubMedCrossRefGoogle Scholar
  30. 30.
    Wong VG. Methotrexate in the therapy of cyclitis. Trans Am Acad Ophthalmol Otolaryngol. 1965;69:279–93.Google Scholar
  31. 31.
    Okada AA. Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature. Ocul Immunol Inflamm. 2005;13:335–51.PubMedCrossRefGoogle Scholar
  32. 32.
    Kaplan-Messas A, Barkana Y, Avni I, et al. Methotrexate as a first-line corticosteroid-sparing therapy in a cohort of uveitis and scleritis. Ocul Immunol Inflamm. 2003;11:131–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Shah SS, Lowder CY, Schmitt MA, et al. Low-dose methotrexate therapy for ocular inflammatory disease. Ophthalmology. 1992;99:1419–23.PubMedCrossRefGoogle Scholar
  34. 34.
    Samson CM, Waheed N, Baltatzis S, et al. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology. 2001;108:1134–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Bom S, Zamiri P, Lightman S. Use of methotrexate in the management of sight-threatening uveitis. Ocul Immunol In Flamm. 2001;9:35–40.CrossRefGoogle Scholar
  36. 36.
    Malik AR, Pavesio C. The use of low dose methotrexate in children with chronic anterior and intermediate uveitis. Br K Ophthalmol. 2005;89:806–8.CrossRefGoogle Scholar
  37. 37.
    Wessels JA, Huizinga TW, Guchelaar HJ. Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology (Oxford). 2008;47:249–55.CrossRefGoogle Scholar
  38. 38.
    Gangaputra S, Newcomb CW, Liesegang TL, et al. Methotrexate for ocular inflammatory diseases. Ophthalmology. 2009;116(11):2188–98.PubMedCentralPubMedCrossRefGoogle Scholar
  39. 39.
    Saw VP, Dart JK. Ocular mucous membrane pemphigoid: diagnosis and management strategies. Ocul Surf. 2008;6:128–42.PubMedCrossRefGoogle Scholar
  40. 40.
    Van Ede AE, Laan RF, Blom HJ, et al. Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Semin Arthritis Rheum. 1998;27:277–97.PubMedCrossRefGoogle Scholar
  41. 41.
    Walker AM, Funch D, Dreyer NA, et al. Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Arthritis Rheum. 1993;36:329–35.PubMedCrossRefGoogle Scholar
  42. 42.
    Tolman KG, Clegg DO, Lee RG, et al. Methotrexate and the liver. J Rheumatol Suppl. 1985;12:29–34.PubMedGoogle Scholar
  43. 43.
    Hoekstra M, van Ede AE, Haagsma CJ, et al. Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis. 2003;62:423–6.PubMedCentralPubMedCrossRefGoogle Scholar
  44. 44.
    Lahdenne P, Rapola J, Ylijoki H, et al. Hepatoxicity in patients with juvenile idiopathic arthritis receiving longterm methotrexate therapy. J Rheumatol. 2002;29:2442–5.PubMedGoogle Scholar
  45. 45.
    Suwa A, Hirakata M, Satoh S, et al. Rheumatoid arthritis associated with methotrexate-induced pneumonitis: improvement with i.v. cyclophosphamide therapy. Clin Exp Rheumatol. 1999;17:355–8.PubMedGoogle Scholar
  46. 46.
    Salaffi F, Manganelli P, Carotti M, et al. Methotrexate-induced pneumonitis in patients with rheumatoid arthritis and psoriatic arthritis: report of five cases and review of the literature. Clin Rheumatol. 1997;16:296–304.PubMedCrossRefGoogle Scholar
  47. 47.
    Cottin V, Tébib J, Massonnet B, et al. Pulmonary function in patients receiving long-term low-dose methotrexate. Chest. 1996;109:933–9.PubMedCrossRefGoogle Scholar
  48. 48.
    Hilliquin P, Renoux M, Perrot S, et al. Occurrence of pulmonary complications during methotrexate therapy in rheumatoid arthritis. Br J Rheumatol. 1996;35:441–5.PubMedCrossRefGoogle Scholar
  49. 49.
    Kempen JH, Gangaputra S, Daniel E, et al. Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. Am J Ophthalmol. 2008;146:802–12.PubMedCentralPubMedCrossRefGoogle Scholar
  50. 50.
    Miserocchi E, Baltatzis S, Roque MR, et al. The effect of treatment and its related side effects in patients with severe ocular cicatricial pemphigoid. Ophthalmology. 2002;109:111–8.PubMedCrossRefGoogle Scholar
  51. 51.
    Baker KB, Spurrier NJ, Watkins AS, et al. Retention time for corticosteroid-sparing systemic immunosuppressive agents in patients with inflammatory eye disease. Br J Ophthalmol. 2006;90:1481–5.PubMedCentralPubMedCrossRefGoogle Scholar
  52. 52.
    Bawle EV, Conard JV, Weiss L. Adult and two children with fetal methotrexate syndrome. Teratology. 1998;57:51–5.PubMedCrossRefGoogle Scholar
  53. 53.
    Lewden B, Vial T, Elefant E, et al. Low dose methotrexate in the first trimester of pregnancy: results of a French collaborative study. J Rheumatol. 2004;31:2360–5.PubMedGoogle Scholar
  54. 54.
    Pasadhika S, Kempen JH, Newcomb CW, et al. Azathioprine for ocular inflammatory diseases. Am J Ophthalmol. 2009;148(4):500–9.PubMedCentralPubMedCrossRefGoogle Scholar
  55. 55.
    Elion GB. The purine path to chemotherapy. Science. 1989;244(4900):41–7.PubMedCrossRefGoogle Scholar
  56. 56.
    Patel AA, Swerlick RA, McCall CO. Azathioprine in dermatology: the past, the present, and the future. J Am Acad Dermatol. 2006;55(3):369–89.PubMedCrossRefGoogle Scholar
  57. 57.
    Elion GB, Callahan SW, Hitchings GH, et al. The metabolism of 2-amino-6-(1-methyl-4-nitro-5-imidazolyl) thiopurine (B.W. 57–323) in man. Cancer Chemother Rep 1. 1960;8:47–52.Google Scholar
  58. 58.
    Thiersch JB. Effect of 6-(1'-methyl-4'-nitro-5'-imidazolyl)-mercaptopurine and 2-amino-6-(1'-methyl-4'-nitro-5'-imidazolyl)-mercaptopurine on the rat litter in utero. J Reprod Fertil. 1962;4:297–302.PubMedCrossRefGoogle Scholar
  59. 59.
    Murray JE, Merrill JP, Harrison JH, et al. Prolonged survival of human-kidney homografts by immunosuppressive drug therapy. New Engl J Med. 1963;268(24):1315–23.PubMedCrossRefGoogle Scholar
  60. 60.
    Dave VK, Vickers CF. Azathioprine in the treatment of muco-cutaneous pemphigoid. Br J Dermatol. 1974;90:183–6.PubMedCrossRefGoogle Scholar
  61. 61.
    Ward JR. Role of disease-modifying antirheumatic drugs versus cytotoxic agents in the therapy of rheumatoid arthritis. Am J Med. 1988;85:39–44.PubMedCrossRefGoogle Scholar
  62. 62.
    Danovitch GM. Choice of immunosuppressive drugs and individualization of immunosuppressive therapy for kidney transplant patients. Transplant Proc. 1999;31:2S–6.PubMedCrossRefGoogle Scholar
  63. 63.
    Wise M, Callen JP. Azathioprine: a guide for the management of dermatology patients. Dermatol Ther. 2007;20:206–15.PubMedCrossRefGoogle Scholar
  64. 64.
    Gisbert JP, Niño P, Cara C, et al. Comparative effectiveness of azathioprine in Crohn’s disease and ulcerative colitis: prospective, long-term, follow-up study of 394 patients. Aliment Pharmacol Ther. 2008;28:228–38.PubMedCrossRefGoogle Scholar
  65. 65.
    Lee JC, Gladman DD, Schentag CT, et al. The long-term use of azathioprine in patients with psoriatic arthritis. J Clin Rheumatol. 2001;7:160–5.PubMedCrossRefGoogle Scholar
  66. 66.
    Goldstein LH, Dolinsky G, Greenberg R, et al. Pregnancy outcome of women exposed to azathioprine during pregnancy. Birth Defects Res A Clin Mol Teratol. 2007;79:696–701.PubMedCrossRefGoogle Scholar
  67. 67.
    Alstead EM, Ritchie JK, Lennard-Jones JE, et al. Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology. 1999;99:443–6.Google Scholar
  68. 68.
    Baltatzis S, Tufail F, Yu EN, et al. Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders. Ophthalmology. 2003;110:1061–5.PubMedCrossRefGoogle Scholar
  69. 69.
    Behrend M. A review of clinical experience with the novel immunosuppressive drug mycophenolate mofetil in renal transplantation. Clin Nephrol. 1996;45:336–41.PubMedGoogle Scholar
  70. 70.
    Zurdel J, Aboalchamat B, Zierhut M, et al. Early clinical experiences with mycophenolate mofetil for immunosuppressive therapy of ocular cicatricial pemphigoid [in German]. Klin Monbl Augenheilkd. 2001;218:222–8.PubMedCrossRefGoogle Scholar
  71. 71.
    Larkin G, Lightman S. Mycophenolate mofetil: a useful immunosuppressive in inflammatory eye disease. Ophthalmology. 1999;106:370–4.PubMedCrossRefGoogle Scholar
  72. 72.
    Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation. 1995;60:225–32.PubMedCrossRefGoogle Scholar
  73. 73.
    Boumpas DT, Kritikos HD, Daskalakis NG. Perspective on future therapy of vasculitis. Curr Rheumatol Rep. 2000;2:423–9.PubMedCrossRefGoogle Scholar
  74. 74.
    Adu D, Cross J, Jayne DR. Treatment of systemic lupus erythematosus with mycophenolate mofetil. Lupus. 2001;10:203–8.PubMedCrossRefGoogle Scholar
  75. 75.
    Meihsler W, Reinisch W, Moser G, et al. Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with chronic active Crohn’s disease? Am J Gastroenterol. 2001;96:782–7.CrossRefGoogle Scholar
  76. 76.
    Schwarz A. New aspects of the treatment of nephrotic syndrome. J Am Soc Nephrol. 2001;12 Suppl 17:S44–7.PubMedGoogle Scholar
  77. 77.
    Chanaud III NP, Vistica BP, Eugui E, et al. Inhibition of experimental autoimmune uveoretinitis by mycophenolate mofetil, an inhibitor of purine metabolism. Exp Eye Res. 1995;61:429–34.PubMedCrossRefGoogle Scholar
  78. 78.
    Budde K, Glander P, Bauer S, et al. Pharmacodynamic monitoring of mycophenloate mofetil. Clin Chem Lab Med. 2000;38:1213–6.PubMedCrossRefGoogle Scholar
  79. 79.
    Ahsan N, Johnson C, Gonwa T, et al. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years. Transplantation. 2001;72:245–50.PubMedCrossRefGoogle Scholar
  80. 80.
    Thorne JE, Jabs DA, Qazi FA, et al. Mycophenolate mofetil therapy for inflammatory eye disease. Am Acad Ophthalmology. 2005;112:1472–7.CrossRefGoogle Scholar
  81. 81.
    Doycheva D, Deuter C, Blumenstock G, et al. Long-term results of therapy with mycophenolate mofetil in ocular mucous membrane pemphigoid. Ocul Immunol Inflamm. 2011;19:431–8.PubMedCrossRefGoogle Scholar
  82. 82.
    Nottage JM, Hammersmith KM, Murchison AP, et al. Treatment of mucous membrane pemphigoid with mycophenolate mofetil. Cornea. 2013;32(6):810–5.PubMedCrossRefGoogle Scholar
  83. 83.
    Daniel E, Thorne JE, Newcomb CW, et al. Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol. 2010;149(3):423–32.PubMedCentralPubMedCrossRefGoogle Scholar
  84. 84.
    Saw VP, Dart JK, Rauz S, et al. Immunosuppressive therapy for ocular mucous membrane pemphigoid strategies and outcomes. Ophthalmology. 2008;115:253–61.PubMedCrossRefGoogle Scholar
  85. 85.
    Galor A, Jabs DA, Leder HA, et al. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology. 2008;115:1826–32.PubMedCrossRefGoogle Scholar
  86. 86.
    Pleyer U, Ruokonen P, Schmidt N, et al. Mycophenol acid in ocular autoimmune disorders-can we optimize this therapy? [in German]. Klin Monbl Augenheilkd. 2008;225:66–9.PubMedCrossRefGoogle Scholar
  87. 87.
    Kilmartin DJ, Forrester JV, Dick AD. Rescue therapy with mycophenolate mofetil in refractory uveitis [letter]. Lancet. 1998;352:35–6.PubMedCrossRefGoogle Scholar
  88. 88.
    Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: golden anniversary. Nature Reviews. Clin Oncol. 2009;6(11):638–47.Google Scholar
  89. 89.
    Elder MJ, Jones RJ, Brodsky RA. Role of cyclophosphamide and high dose steroid in ocular cicatricial pemphigoid. Br J Ophthalmology. 1995;79:264–6.CrossRefGoogle Scholar
  90. 90.
    Roda PE. Nitrogen mustard therapy of uveitis of unknown etiology. Rev Clin Esp. 1952;44:173–80.Google Scholar
  91. 91.
    Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492–513.PubMedCrossRefGoogle Scholar
  92. 92.
    Pujari SS, Kempen JH, Newcomb CW, et al. Cyclophosphamide of ocular inflammatory diseases. Ophthalmology. 2010;117(2):356.PubMedCentralPubMedCrossRefGoogle Scholar
  93. 93.
    Hemady R, Tauber J, Foster CS. Immunosuppressive drugs in immune and inflammatory ocular disease. Surv Ophthalmol. 1991;35:369–85.PubMedCrossRefGoogle Scholar
  94. 94.
    Mondino BJ. Cicatricial pemphigoid and erythema multiforme. Ophthalmology. 1990;97:939–52.PubMedCrossRefGoogle Scholar
  95. 95.
    Tauber J, Sainz de la Maza M, Foster CS. Systemic chemotherapy for ocular cicatricial pemphigoid. Cornea. 1991;10:185–95.PubMedCrossRefGoogle Scholar
  96. 96.
    Yesudian PD, Armstrong S, Cawood JI, et al. Mucous membrane pemphigoid: management of advanced ocular disease with intravenous cyclophosphamide and amniotic membrane transplantation. Br J Dermatol. 2005;153:692–4.PubMedCrossRefGoogle Scholar
  97. 97.
    Pandya AG, Warren KJ, Bergstresser PR. Cicatricial pemphigoid successfully treated with pulse intravenous cyclophosphamide. Arch Dermatol. 1997;133:245–7.PubMedGoogle Scholar
  98. 98.
    Kaçmaz RO, Kempen JH, Newcomb C, et al. Cyclosporine for ocular inflammatory diseases. Ophthalmology. 2010;117(3):576–84.PubMedCentralPubMedCrossRefGoogle Scholar
  99. 99.
    Berkson BM, Lome LG, Shapiro I. Severe cystitis induced by cyclophosphamide, role of surgical management. JAMA. 1973;225:605–6.PubMedCrossRefGoogle Scholar
  100. 100.
    Park MC, Park YB, Jung SY, et al. Risk of ovarian failure and pregnancy outcome in patients with lupus nephritis treated with intravenous cyclophosphamide pulse therapy. Lupus. 2004;13:569–74.PubMedCrossRefGoogle Scholar
  101. 101.
    Asten P, Barrett J, Symmons D. Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic disease. J Rheumatol. 1999;26:1705–14.PubMedGoogle Scholar
  102. 102.
    Baltus JA, Boersma JW, Hartman AP, et al. The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: a controlled retrospective follow-up. Ann Rheum Dis. 1983;42:368–73.PubMedCentralPubMedCrossRefGoogle Scholar
  103. 103.
    Baker GL, Kahl LE, Zee BC, et al. Malignancy following treatment of rheumatoid arthritis with cyclophosphamide: long-term case–control follow-up study. Am J Med. 1987;83:1–9.PubMedCrossRefGoogle Scholar
  104. 104.
    Ostensen M. Treatment with immunosuppressive and disease modifying drugs during pregnancy and lactation. Am J Reprod Immunol. 1992;28:148–52.PubMedCrossRefGoogle Scholar
  105. 105.
    Rubin B, Palestine AG. Complications of corticosteroid and immunosuppressive drugs. Int Ophthalmol Clin. 1989;29(3):159–71.PubMedCrossRefGoogle Scholar
  106. 106.
    Kaplan AA. Therapeutic plasma exchange: core curriculum 2008. Am J Kidney Dis. 2008;52(6):1180–96.PubMedCrossRefGoogle Scholar
  107. 107.
    Siami GA, Siami FS. Membrane plasmapheresis in the United States: a review over the last 20 years. Ther Apher. 2001;5(4):315–20.PubMedCrossRefGoogle Scholar
  108. 108.
    Szczepiorkowski ZM, Bandarenko N, Kim HC, et al. Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher. 2010;25(3):83–177.PubMedCrossRefGoogle Scholar
  109. 109.
    Hashimoto Y, Suga Y, Yoshiike T, et al. A case of antiepiligrin cicatricial pemphigoid successfully treated by plasmapheresis. Dermatology. 2000;201:58–60.PubMedCrossRefGoogle Scholar
  110. 110.
    Chang B, Tholpady A, Huang R, et al. Clinical and serological responses following plasmapheresis in bullous pemphigoid: two case reports and a review of the literature. Blood Transfus. 2014;12:269–75.PubMedCentralPubMedGoogle Scholar
  111. 111.
    Roujeau JC, Revuz J, Touraine R, et al. Cortico-resistant bullous pemphigoid. Favorable results with plasmapheresis [In French]. Nouv Presse Med. 1979;8:3362.PubMedGoogle Scholar
  112. 112.
    Roujeau JC, Guillaume JC, Morel P, et al. Plasma exchange in bullous pemphigoid. Lancet. 1984;2:486–8.PubMedCrossRefGoogle Scholar
  113. 113.
    Egan CA, Meadows KP, Zone JJ. Plasmapheresis as a steroid saving procedure in bullous pemphigoid. Int J Dermatol. 2000;39(3):230–5.PubMedCrossRefGoogle Scholar
  114. 114.
    Mazzi G, Raineri A, Zanolli FA, et al. Plasmapheresis therapy in pemphigus vulgaris and bullous pemphigoid. Transfus Apher Sci. 2003;28:13–8.PubMedCrossRefGoogle Scholar
  115. 115.
    Gurland HJ, Lysaght MJ, Samtleben W, et al. A comparison of centrifugal and membrane-based apheresis formats. Int J Artif Organ. 1984;7(1):35–8.Google Scholar
  116. 116.
    Yamada H, Yaguchi H, Takamori K, et al. Plasmapheresis for the treatment of pemphigus vulgaris and bullous pemphigoid. Therupeutic A. 1997;1(2):178–82.CrossRefGoogle Scholar
  117. 117.
    Turner MS, Sutton D, Sauder DN. The use of plasmapheresis and immunosuppression in the treatment of pemphigus vulgaris. J Am Acad Dermatol. 2000;43:1058–64.PubMedCrossRefGoogle Scholar
  118. 118.
    Bohn J, Jonsson S, Holst R. Successful treatment of recalcitrant cicatricial pemphigoid with a combination of plasma exchange and cyclophosphamide. Br J of Dermatol. 1999;141:536–40.CrossRefGoogle Scholar
  119. 119.
    Hashimoto Y, Suga Y, Yoshiike T, et al. A case of antiepiligrin cicatricial successfully treated by plasmapheresis. Dermatology. 2001;201:58–60.CrossRefGoogle Scholar
  120. 120.
    Tellier Z. Intravenous immunoglobulin in eye involvement. Clin Rev Allergy Immun. 2005;29:295–306.CrossRefGoogle Scholar
  121. 121.
    Ahmed AR, Dahl MV. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch Dermatol. 2003;139:1051–9.PubMedCrossRefGoogle Scholar
  122. 122.
    Kazatchkine MD. Immunomodulation of autoimmune and inflammatory disease with intravenous immune globulin. N Engl J Med. 2001;345:747–55.PubMedCrossRefGoogle Scholar
  123. 123.
    Tellier Z. Human immunoglobulins in intraocular inflammation. Ann NY Acad Sci. 2007;1110:337–47.PubMedCrossRefGoogle Scholar
  124. 124.
    Neumann R, Tauber J, Foster CS. Remission and recurrence after withdrawal of therapy for ocular cicatricial pemphigoid. Ophthalmology. 1991;98:858–62.PubMedCrossRefGoogle Scholar
  125. 125.
    Mondino BJ, Brown SI. Immunosuppressive therapy in ocular cicatricial pemphigoid. Am J Ophthalmol. 1983;96:453–9.PubMedCrossRefGoogle Scholar
  126. 126.
    Letko E, Miserocchi E, Daoud YJ, et al. A nonradomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies. Clin Immunol. 2004;111:303–10.PubMedCrossRefGoogle Scholar
  127. 127.
    Foster CS, Ahmed AR. Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid. Am Acad Ophthalmology. 1999;106:2136–43.CrossRefGoogle Scholar
  128. 128.
    Sami N, Bhol KC, Razzaque AA, et al. Intravenous immunoglobulin therapy in patients with multiple mucosal involvement in mucous membrane pemphigoid. Clin Immunol. 2002;102:59–67.PubMedCrossRefGoogle Scholar
  129. 129.
    Foster CS, Chang PY, Ahmed AR. Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid. Am Acad Ophthalmology. 2010;117:861–9.CrossRefGoogle Scholar
  130. 130.
    Ross AH, Jaycock P, Cook SD, et al. The use of rituximab in refractory mucous membrane pemphigoid with severe ocular involvement. Br J Ophthalmol. 2009;93:421–2, 548.PubMedCrossRefGoogle Scholar
  131. 131.
    Schumann T, Schmidt E, Booken N, et al. Successful treatment of mucous membrane pemphigoid with the anti-CD-20 antibody rituximab [letter]. Acta Derm Venereol. 2009;89:101–2.PubMedCrossRefGoogle Scholar
  132. 132.
    Gurcan HM, Keskin DB, Stern JN, et al. A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol. 2009;9:10–25.PubMedCrossRefGoogle Scholar
  133. 133.
    El Tal AK, Posner MR, Spigelman Z, et al. Rituximab: a monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris. J Am Acad Dermatol. 2006;55:449–59.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Swetha Dhanireddy
    • 1
  • Armin Maghsoudlou
    • 1
  • Janine M. Preble
    • 1
  • Malinga D. Ratwatte
    • 1
    • 2
  • C. Stephen Foster
    • 1
    • 3
    Email author
  1. 1.Massachusetts Eye Research and Surgery Institution, Ocular Immunology and Uveitis FoundationCambridgeUSA
  2. 2.School of Clinical MedicineUniversity of CambridgeCambridgeUK
  3. 3.Department of OphthalmologyHarvard Medical SchoolBostonUSA

Personalised recommendations